Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells

Anti-Cancer Drugs

Volumn 26, Issue 3, 2015, Pages 284-292

  Ongaro, Alessia ^a   Pellati, Agnese ^a   De Mattei, Monica ^a   De Terlizzi, Francesca ^b   Rossi, Carlo R ^c   Campana, Luca G ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b Laboratory of Clinical Biophysics IGEA SpA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

buthionine sulfoximine; electrochemotherapy; electroporation; melanoma cells; melphalan

Indexed keywords

BUTHIONINE SULFOXIMINE; GLUTATHIONE; MELPHALAN; ALKYLATING AGENT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PERMEABILIZATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INACTIVATION; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ELECTROCHEMOTHERAPY; ELECTROPORATION; ENZYMATIC ASSAY; HUMAN; HUMAN CELL; IC50; MELANOMA CELL; MELANOMA CELL LINE; PRIORITY JOURNAL; TREATMENT DURATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; MELANOMA; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ELECTROPORATION; GLUTATHIONE; HUMANS; MELANOMA; MELPHALAN;

EID: 84925467097     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000192     Document Type: Article

References (47)

1. Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg 2007; 60:32-40.
2. Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005; 12:587-596.
3. Zogakis TG, Essner R, Wang HJ, Turner RR, Takasumi YT, Gaffney RL, et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg 2005; 140:865-871, discussion 871-872.
4. Nieweg OE, Kroon BB. Isolated limb perfusion with melphalan for melanoma. J Surg Oncol 2014; 109:332-337.
5. Kroon HM, Huismans AM, Kam PC, Thompson JF. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. J Surg Oncol 2014; 109:348-351.
6. Hansson J, Lewensohn R, Ringborg U, Nilsson B. Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 1987; 47:2631-2637.
7. Di Filippo F, Giacomini P, Rossi CR, Santinami M, Anzà M, Garinei R, et al. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNF alpha-based isolated limb perfusion. In Vivo 2009; 23:347-352.
8. Deroose JP, Eggermont AM, van Geel AN, deWilt JH, Burger JW, Verhoef C. 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol 2012; 19:627-635.
9. Hoekstra HJ, Veerman K, van Ginkel RJ. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion J Surg Oncol 2014; 109:338-347.
10. Renard N, Nooijen PT, Schalkwijk L, deWaal RM, Eggermont AM, Liénard D, et al. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol 1995; 176:279-287.
11. Folli S, Pèlegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993; 53:829-836.
12. De Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82:1000-1003.
13. Rothbarth J, Vahrmeijer AL, Mulder GJ. Modulation of cytostatic efficacy of melphalan by glutathione: mechanisms and efficacy. Chem Biol Interact 2002; 140:93-107.
14. Grubbs EG, Abdel-Wahab O, Cheng TY, Abdel-Wahab Z, Peterson B, Pruitt SK, et al. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J Am Coll Surg 2004; 199:419-427.
15. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, et al. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drugresistant and-sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985; 34:2583-2586.
16. Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds CP. Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res 1999; 246:183-192.
17. Grubbs EG, Ueno T, Abdel-Wahab O, Cheng TY, Pruitt SK, Michael Colvin O, et al. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 2004; 136:210-218.
18. Pu Q, Bianchi P, Bezwoda WR. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNAcrosslinks, cell cycle analysis, and glutathione content in the melphalansensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL). Anticancer Res 2000; 20:2561-2568.
19. Goldenberg GJ, Lam HY, Begleiter A. Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J Biol Chem 1979; 254:1057-1064.
20. Mir LM, Orlowski S. Mechanisms of electrochemotherapy. Adv Drug Deliv Rev 1999; 35:107-118.
21. Mir LM. Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry 2001; 53:1-10.
22. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29:371-387.
23. Rols MP. Electropermeabilization, a physical method for the delivery of therapeutic molecules into cells. Biochim Biophys Acta 2006; 1758:423-428.
24. Miklavi D, Mali B, Kos B, Heller R, Serša G. Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online 2014; 13:29.
25. Yarmush ML, Golberg A, Serša G, Kotnik T, Miklavi D. Electroporationbased technologies for medicine: principles, applications, and challenges. Annu Rev Biomed Eng 2014; 16:295-320.
26. Orlowski S, Belehradek J Jr, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988; 37:4727-4733.
27. Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 1998; 9:319-325.
28. Campana L, Mocellin S, Basso M, Puccetti O, De Salvo G, Chiarion-Sileni V, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009; 16:191-199.
29. Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 2012; 99:821-830.
30. Queirolo P, Marincola F, Spagnolo F. Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. Arch Dermatol Res 2014; 306:521-526.
31. Matthiessen LW, Johannesen HH, Hendel HW, Moss T, Kamby C, Gehl J. Electrochemotherapy for large cutaneous recurrence of breast cancer: a phase II clinical trial. Acta Oncol 2012; 51:713-721.
32. Ruscoe JE, Rosario LA, Wang T, Gaté L, Arifoglu P, Wolf CR, et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 2001; 298:339-345.
33. Kramer RA, Greene K, Ahmad S, Vistica DT. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res 1987; 47:1593-1597.
34. O'Dwyer PJ, Hamilton TC, Young RC, LaCreta FP, Carp N, Tew KD, et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst 1992; 84:264-267.
35. Rodriguez-Vicente J, Vicente-Ortega V, Canteras-Jordana M. The effects of different antineoplastic agents and of pretreatment by modulators on three melanoma lines. Cancer 1998; 82:495-502.
36. Prezioso JA, FitzGerald GB, Wick MM. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. J Invest Dermatol 1992; 99:289-293.
37. Benathan M, Alvero-Jackson H, Mooy AM, Scaletta C, Frenk E. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells. Melanoma Res 1992; 2:305-314.
38. Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ. Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. Cancer Chemother Pharmacol 1997; 40:38-44.
39. McNeely SC, Belshoff AC, Taylor BF, Fan TW, McCabe MJ Jr, Pinhas AR, States JC. Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest. Toxicol Appl Pharmacol 2008; 229:252-261.
40. Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a phase I trial of melphalan and BSO. Cancer Res 1995; 55:4507-4511.
41. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14:249-256.
42. Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997; 89:1789-1796.
43. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2013; 39:4-16.
44. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, et al. Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 2010; 23:651-661.
45. Roberts MS, Wu ZY, Siebert GA, Thompson JF, Smithers BM. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res 2001; 11:611-618.
46. Defty CL, Marsden JR. Melphalan in regional chemotherapy for locally recurrent metastatic melanoma. Curr Top Med Chem 2012; 12:53-60.
47. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24:4196-4201.